Aptevo Therapeutics Shares Are Trading Higher After the Company Announced That All Three Patients in Cohort 1 of Its Bispecific Mipletamig Frontline AML Trial Achieved Remission Within 30 Days.
Aptevo Therapeutics Shares Are Trading Higher After the Company Announced That All Three Patients in Cohort 1 of Its Bispecific Mipletamig Frontline AML Trial Achieved Remission Within 30 Days.
Aptevo Therapeutics的股票在公司宣佈其雙特異性Mipletamig前線AML試驗中的第一組所有三名患者在30天內達到了緩解後，股價上升。
Aptevo Therapeutics Shares Are Trading Higher After the Company Announced That All Three Patients in Cohort 1 of Its Bispecific Mipletamig Frontline AML Trial Achieved Remission Within 30 Days.
Aptevo Therapeutics的股票在公司宣佈其雙特異性Mipletamig前線AML試驗中的第一組所有三名患者在30天內達到了緩解後，股價上升。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。